Atrial fibrillation carries a serious risk: a clot forming in a poorly contracting left atrium can break loose and cause a stroke. Anticoagulation cuts that risk substantially, but it isn’t free of downside, so clinicians need a reliable way to estimate how much stroke risk a given patient actually carries before deciding whether the trade-off is worth it. CHA₂DS₂-VASc has been that tool for over a decade. More recently, a second version — CHA₂DS₂-VA — has entered the picture, and the two don’t always agree. Here’s what changed, and why.

What CHA₂DS₂-VASc measures

CHA₂DS₂-VASc is a simple point system built from eight easily documented clinical facts: congestive heart failure, hypertension, age, diabetes, prior stroke or thromboembolism, vascular disease, the 65–74 age band, and female sex. Most criteria are worth one point; age ≥75 and prior stroke are weighted double because they carry outsized risk on their own. Add them up, and the total maps to an estimated annual stroke risk — the higher the score, the stronger the case for anticoagulation. It was derived by Lip and colleagues in 2010 from the Euro Heart Survey, refining an older, cruder score (CHADS₂) that missed a meaningful slice of at-risk patients.

Why a sex-free version now exists

Female sex has been part of the score since the beginning, added because early data showed women with atrial fibrillation had a higher stroke rate than men with an otherwise identical risk profile. But later, larger analyses complicated that picture: female sex looked less like an independent risk factor and more like something that interacts with the other criteria — its apparent effect showed up mainly in women who already had other risk factors, and largely disappeared in women with none. That distinction matters clinically, because it means a woman with zero other risk factors probably shouldn’t be treated as automatically higher-risk than a man with the same, otherwise empty, profile just because of the one sex point.

The 2024 ESC atrial fibrillation guideline responded by promoting CHA₂DS₂-VA — the identical score with the sex criterion simply removed — to the primary recommended tool, while flagging sex as a risk modifier to weigh qualitatively rather than a point to add mechanically. US guidance (the 2019 AHA/ACC/HRS update) still references the classic VASc version, so in practice, clinicians will keep encountering both scores for some time yet.

When do the two scores actually disagree?

Only when sex is the deciding point. A man’s CHA₂DS₂-VASc and CHA₂DS₂-VA scores are always identical, since the sex criterion contributes nothing for men either way. For women, the two scores are identical whenever she has at least one other risk factor, because the sex point simply adds 1 to both running totals in that case. They diverge only in the specific situation of a woman whose sole point comes from sex itself — where VASc says “1” and VA says “0.” That’s a narrow band, but it sits close to the treatment threshold, which is exactly where the disagreement matters most.

A quick example

An 80-year-old woman with a prior ischemic stroke and no other risk factors scores CHA₂DS₂-VASc = 5 (2 points for age, 2 for the stroke, 1 for sex) and CHA₂DS₂-VA = 4 (dropping the sex point). Both numbers land well above the threshold where anticoagulation is recommended rather than merely considered, so in this case the discrepancy is academic — the prior stroke alone settles the question. The gap becomes more consequential in lower-scoring patients sitting right at a treatment threshold, which is exactly the population worth double-checking against both versions.

Editverse’s free CHA₂DS₂-VASc / CHA₂DS₂-VA calculator computes both scores side by side from the same inputs, so you can see immediately whether a given patient falls into that narrow disagreement zone, along with a fully worked example and anticoagulation-threshold guidance for each version.

Clinical decision-support aid, not a substitute for clinical judgment. This tool implements a published scoring system for education and workflow support. It is not a medical device and has not been reviewed by the FDA or any regulatory body; results should always be interpreted by a qualified clinician alongside the full clinical picture.

References

  1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
  2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125–e151.
  3. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314–3414.
  4. Rivera-Caravaca JM, et al. Validation of the CHA₂DS₂-VA score. Europace. 2024;26(11):euae280.

Researching stroke risk, anticoagulation patterns, or atrial fibrillation prevalence at a population level? Editverse’s NHANES Study service helps investigators go from research question to a manuscript-ready NHANES analysis — cohort definition, weighted survey statistics, and results reporting included.